DOCSLIB.ORG

Meglumine Iodamide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meglumine Iodamide Gadoteric Acid/Iodamide 1481 Preparations cholangiopancreatography, and hysterosalpingography. It is also used for contrast enhancement in computed tomography. USP 31: Gadoversetamide Injection. HO It is usually available as solutions containing 54.84 to 76.78% of Proprietary Preparations (details are given in Part 3) iobitridol (equivalent to 250 to 350 mg/mL of iodine). The dose Arg.: Optimark; Austral.: Optimark; Canad.: Optimark; Cz.: Optimark; O and strength used varies depending on the procedure and route. Port.: Optimark; USA: Optimark. OH ◊ References. HO OH 1. Petersein J, et al. Results of the safety and efficacy of iobitridol in more than 61,000 patients. Eur Radiol 2003; 13: 2006–11. HO Gadoxetic Acid (rINN) Preparations Acide Gadoxétique; Ácido gadoxético; Acidum Gadoxeticum; Pharmacopoeias. In Eur. (see p.vii). Also in USNF. Proprietary Preparations (details are given in Part 3) Gd-EOB-DTPA. Dihydrogen [N-{(2S)-2-[bis(carboxymethyl)- Arg.: Xenetic; Xenetix; Austria: Xenetix; Belg.: Xenetix; Braz.: Henetix†; Ph. Eur. 6.2 (Galactose). A white or almost white, crystalline or Chile: Xenetix; Cz.: Xenetix; Denm.: Xenetix; Fin.: Xenetix; Fr.: Xenetix; amino]-3-(p-ethoxyphenyl)propyl}-N-{2-[bis(carboxymethyl)- finely granulated powder. Freely soluble or soluble in water; very Ger.: Xenetix; Gr.: Xenetix; Hung.: Xenetix; Israel: Xenetix; Ital.: amino]ethyl}glycinato(5−)]gadolinate(2−). slightly soluble in alcohol. Xenetix; Neth.: Xenetix; Norw.: Xenetix; Port.: Xenetix; Spain: Xenetix; Swed.: Xenetix; Switz.: Xenetix; Venez.: Xenetix. Гадоксетовая Кислота USNF 26 (Galactose). A white, crystalline or finely granulated powder. Soluble in water; very slightly soluble in alcohol. Store C23H30GdN3O11 = 681.7. in airtight containers. CAS — 135326-11-3 (gadoxetic acid). Profile Iocetamic Acid (BAN, USAN, pINN) ATC — V08CA10. Galactose is a naturally occurring monosaccharide used as an Acide Iocétamique; Ácido iocetámico; Acidum Iocetamicum; ATC Vet — QV08CA10. ultrasound contrast medium (p.1474); dissolution of galactose DRC-1201; Jocetamsyra; Josetaamihappo; MP-620. N-Acetyl-N- microparticles releases microbubbles of air that provide echo- (3-amino-2,4,6-tri-iodophenyl)-2-methyl-β-alanine; 2-[N-(3- enhancement. Galactose is used to enhance ultrasound imaging Amino-2,4,6-tri-iodophenyl)acetamidomethyl]-propionic acid. + of the female genital tract. It is given transcervically as a micro- 2H Йоцетамовая Кислота O- O- bubble-microparticle suspension prepared immediately before C H I N O = 614.0. Gd+++ use by suspending 3 g of galactose microparticles in 13.5 mL of 12 13 3 2 3 a solution containing 200 mg/mL galactose. The usual dose is 2 CAS — 16034-77-8. O O ATC — V08AC07. O O to 5 mL, with additional doses of 1 to 2 mL as required, to a max- NN imum of 30 mL. Similar suspensions of galactose, with palmitic ATC Vet — QV08AC07. acid to stabilise the microbubbles, have been used in echocardi- O- O- N ography. H I - The clearance of galactose given intravenously has been used as O a measure of liver function. Galactose labelled with carbon-13 (p.2277) has also been used. I NH2 O Precautions. Preparations that contain, or are metabolised to, galactose may interfere with the results from glucose tests O (p.2314). Overestimation of glucose results may mask hypogly- O N I caemia, resulting in the inappropriate use of insulin.1,2 CH3 CH3 1. Medicines and Healthcare products Regulatory Agency. Medical device alert: ref MDA/2007/058 issued 19 July 2007. Available HO H3CO at: http://www.mhra.gov.uk/PrintPreview/PublicationSP/ Sodium Gadoxetate (rINNM) CON2031807 (accessed 01/07/08) Description. Iocetamic acid contains about 62% of I. 2. FDA. Important safety information on interference with blood Gadoxétate de Sodium; Gadoxetate Disodium (USAN); Gadoxe- glucose measurement following use of parenteral mal- Profile tate Sodium; Gadoxetato de sodio; Natrii Gadoxetas; ZK- tose/parenteral galactose/oral xylose-containing products (is- Iocetamic acid is an ionic monomeric iodinated radiographic 139834. sued November 2005). Available at: http://www.fda.gov/cber/ contrast medium with similar properties to iopanoic acid safety/maltose110405.htm (accessed 01/07/08) (p.1484). It is absorbed from the gastrointestinal tract and excret- Натрий Гадоксетат Preparations ed in bile and has been given orally for cholecystography. C H GdN Na O = 725.7. 23 28 3 2 11 Proprietary Preparations (details are given in Part 3) Preparations CAS — 135326-22-6. Arg.: Levovist†; Austral.: Levovist; Austria: Echovist; Levovist†; Om- Proprietary Preparations (details are given in Part 3) ATC — V08CA10. bravist†; Canad.: Echovist†; Levovist†; Cz.: Levovist†; Denm.: Levovist†; Neth.: Cholebrine†. Fin.: Echovist†; Levovist†; Fr.: Echovist; Levovist; Ger.: Echovist; Levovist; ATC Vet — QV08CA10. Hung.: Echovist; Israel: Echovist; Ital.: Levovist; Neth.: Echovist†; Levovist; Norw.: Levovist†; NZ: Levovist; Port.: Levovist; S.Afr.: Echovist†; Spain: Adverse Effects and Precautions Levograf; Levovist; Swed.: Echovist; Levovist†; Switz.: Levovist; UK: Echo- As for Gadopentetic Acid, p.1479. vist; Levovist†. Iodamide (BAN, USAN, rINN) Ametriodinic Acid; B-4130; Iodamida; Iodamidum; Jodamid; Jodi- Pharmacokinetics Multi-ingredient: Gr.: L-Vist. amidi; SH-926. α,5-Diacetamido-2,4,6-tri-iodo-m-toluic acid; 3- Gadoxetate is distributed into the extracellular space after intra- venous injection and is also taken up by the liver. It is less than Acetamido-5-acetamidomethyl-2,4,6-tri-iodobenzoic acid. 10% bound to plasma proteins. It is excreted in about equal Йодамид Iobitridol (BAN, rINN) amounts in the bile and in the urine. An elimination half-life of C12H11I3N2O4 = 627.9. about 1 hour has been reported. Gadoxetate is removed by Iobitridolum; Jobitridol; Jobitridoli. N,N′-Bis(2,3-dihydroxypro- CAS — 440-58-4. haemodialysis. pyl)-5-[2-(hydroxymethyl)hydracrylamido]-2,4,6-triiodo-N,N′- ATC — V08AA03. dimethylisophthalamide; . ATC Vet — QV08AA03. Uses and Administration Gadoxetic acid is an ionic gadolinium chelate with actions simi- Йобитридол lar to those of gadopentetic acid (p.1480). It has paramagnetic C20H28I3N3O9 = 835.2. O CH3 properties and is used as a magnetic resonance contrast medium CAS — 136949-58-1. O I (p.1474). It is taken up by the liver and excreted in bile and is ATC — V08AB11. used in imaging of the liver. NH ATC Vet — QV08AB11. HO Gadoxetic acid is given intravenously as the sodium salt. It is available as a solution containing sodium gadoxetate 181.4 mg/mL (0.25 mmol/mL). The usual dose is 0.1 mL/kg OH I I (0.025 mmol/kg). CH Preparations 3 HN HO N Proprietary Preparations (details are given in Part 3) I O Austria: Primovist; Cz.: Primovist; Fin.: Primovist; Gr.: Primovist; Hung.: H3CO Primovist; Neth.: Primovist; Norw.: Primovist; Swed.: Primovist; Switz.: O Primovist; UK: Primovist. I Description. Iodamide contains about 60.6% of I. Pharmacopoeias. In Jpn. H3C N O Galactose (USAN) I HN OH Meglumine Iodamide (BANM, rINNM) D-Galactopyranose; α-D-Galactopyranose; Galactosa; D-Galac- HO Iodamida de meglumina; Iodamide Meglumine (USAN); Iodamide tose; Galactosum; Galaktoosi; Galaktos; Galaktosa; Galaktóz; OH Méglumine; Meglumini Iodamidum. The N-methylglucamine salt Galaktoza; Galaktoze˙. of iodamide. OH C6H12O6 = 180.2. Меглумина Йодамид CAS — 59-23-4 (D-galactose); 3646-73-9 (α-D-galac- Profile C12H11I3N2O4,C7H17NO5 = 823.2. CAS — 18656-21-8. tose). Iobitridol is a nonionic monomeric iodinated radiographic con- ATC — V04CE01; V08DA02 (microparticles of galactose). trast medium (see p.1474). It may be given intravenously, intra- ATC — V08AA03. ATC Vet — QV08AA03. ATC Vet — QV04CE01; QV08DA02 (microparticles of ga- arterially, or by instillation into body cavities and is used in a lactose). wide range of procedures including angiography, arthrography, Description. Meglumine iodamide contains about 46.3% of I. The symbol † denotes a preparation no longer actively marketed The symbol ⊗ denotes a substance whose use may be restricted in certain sports (see p.vii) 1482 Contrast Media Sodium Iodamide (BANM, rINNM) Because it is slowly metabolised to release iodine, iodised oil is Iodixanol is usually available as a solution containing between Iodamida sódica; Iodamide Sodique; Iodamide Sodium; Natrii Io- used in the management of iodine deficiency (p.2170). 30.5 and 65.2% of iodixanol (equivalent to between 150 and 320 mg/mL of iodine). The dose and strength used vary accord- Infertility. For reference to the use of iodised oil in the manage- damidum. ing to the procedure and route. Натрий Йодамид ment of infertility, see Hysterosalpingography under Adverse Ef- fects and Precautions, above. ◊ References. C12H10I3N2NaO4 = 649.9. CAS — 10098-82-5. Malignant neoplasms. Intra-arterial injection of iodised oil 1. Spencer CM, Goa KL. Iodixanol: a review of its pharmacody- namic and pharmacokinetic properties and diagnostic use as an ATC — V08AA03. has been used in both the diagnosis and management of malig- x-ray contrast medium. Drugs 1996; 52: 899–927. ATC Vet — QV08AA03. nant neoplasms of the liver (p.667). After injection into the he- patic artery, iodised oil is selectively retained by hepatic carcino- Preparations Description. Sodium iodamide contains about 58.6% of I. mas and may have a role as an adjunct to computed tomography USP 31: Iodixanol Injection. Profile for both diagnosis and monitoring.1-3 It has also been used in the Proprietary Preparations (details are given in Part 3) Iodamide is an ionic monomeric iodinated radiographic contrast management of hepatic
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • Mri Contrast Medium and Diagnostic Method
    Europa.schesP— || | MMMMI 1 1||||| 1 1 1 1 1 1||| || J European Patent Office _ o it r- a 4 © Publication number: 0 673 655 A1 Office_„. europeen des brevets © EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC © Application number: 93906789.8 © Int. CI.6: A61 K 49/00 @ Date of filing: 18.03.93 © International application number: PCT/JP93/00322 © International publication number: WO 93/18795 (30.09.93 93/24) ® Priority: 19.03.92 JP 93561/92 Kanagawa 211 (JP) Inventor: IWAI, Hlroyuki, Yodogawa Works of @ Date of publication of application: Daikin Ind.Ltd.s 27.09.95 Bulletin 95/39 1-1, Nlshlhltotsuya Settsu-shl, © Designated Contracting States: Osaka 566 566 (JP) DE FR GB IT Inventor: YAMASHITA, Tsuneo, Yodogawa Works © Applicant: DAIKIN INDUSTRIES, LIMITED of Daikin Ind. Ltd., Umeda Center Building, 4-12, Nakazaki-nishi 1-1, Nishihitotsuya 2-chome Settsu-shi, Kita-ku Osaka 566 566 (JP) Osaka-shi Inventor: SHIMOKAWA, Kazuhiro, Yodogawa Osaka 530 (JP) Works of Daikin Ind. Ltd., © Inventor: YOSHIKAWA, Kohki 1-1, Nishihitotsuya 14-23, Kami-saginomiya 5-chome, Settsu-shi, Nakano-ku Osaka 566 (JP) Tokyo 165 (JP) Inventor: SHIONO, Takahiro, Kanto Rohsai Hospital © Representative: TER MEER - MULLER - 2035, Kizuki Sumiyoshi-cho, STEINMEISTER & PARTNER Nakahara-ku Mauerkircherstrasse 45 Kawasaki-shi, D-81679 Munchen (DE) ^ © MRI CONTRAST MEDIUM AND DIAGNOSTIC METHOD. in m CO © An MRI contrast medium (suspension) comprising an oily fatty acid, fatty acid ester or perfluorinated compound and a particulate paramagnetic compound contained therein. It can be used stably for long and can ^ be administered to a target region, whereby its dose can be reduced.
    [Show full text]
  • Reference List Concerning Spinal Adhesive Arachnoiditis
    SPINAL ADHESIVE ARACHNOIDITIS RMA ID Reference List for RMA363-2 as at June 2020 Number Abel TJ, Howard MA 3rd, Menezes A (2014). Syringomyelia and spinal arachnoiditis resulting from aneurysmal subarachnoid hemorrhage: 94310 Report of two cases and review of the literature. J Craniovertebr Junction Spine, 5(1): 47-51. Abhinav K, Bradley M, Aquilina K, et al (2012). Spinal arachnoiditis and 72882 cyst formation with subarachnoid haemorrhage. Br J Neurosurg, 26(4): 574-5. Abouleish E, Vega S, Blendinger I, et al (1975). Long-term follow-up of 94392 epidural blood patch. Anesth Analg, 54(4): 459-63. Agrawal A, Agrawal A, Agrawal C, et al (2006). An unusual spinal 59948 arachnoiditis. Clin Neurol Neurosurg, 108(8): 775-9. Al Maach N, Vogels OJ, Bollen TL, et al (2010). Arachnoiditis and 59949 communicating hydrocephalus as a complication of epidural blood patch. J Neurol, 257(4): 672-3. Aldrete JA (2003). Neurologic deficits and arachnoiditis following 59950 neuroaxial anesthesia. Acta Anaesthesiol Scand, 47(1): 3-12. Aldrete JA (2004). [Comment] Chronic adhesive arachnoiditis. Br J 59947 Anaesth, 93(2): 301; Author reply 301-3. Aldrete JA, Brown TL (1997). [Comment] Intrathecal hematoma and 94322 arachnoiditis after prophylactic blood patch through a catheter. Anesth Analg, 84(1): 233-4. Anderson TL, Morris JM, Wald JT, et al (2017). Imaging appearance of 94311 advanced chronic adhesive arachnoiditis: a retrospective review. AJR Am J Roentgenol, 209(3): 648-55. Anim-Somuah M, Smyth R, Howell C (2005). Epidural versus non- 60550 epidural or no analgesia in labour. Cochrane Database Syst Rev, 4: CD000331.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Caracterización Fisicoquímica Y Clínica De Los Medios De Contraste Intravasculares Iodados
    Anales de Radiología México 2008;2:129-140. ARTÍCULOS DE REVISIÓN Dra. Patricia Rodríguez Nava,1 Dr. Ernesto J. Dena Espinoza,1 Caracterización fisicoquímica y Dr. Roberto Basile Lenge,2 Dra. Margarita Fuentes García,3 clínica de los medios de contraste Dr. Gustavo Fink Josephi,4 Dr. Eduardo Marbez Namnum1 intravasculares iodados RESUMEN Objetivo: El propósito de sido aceptado por algunos ra- este artículo es realizar una re- diólogos. La lopromida puede Introducción: El uso de visión bibliográfica sobre las ca- ser considerada un agente uni- medios de contraste intravascu- racterísticas, clasificación, pro- versal para todas las explora- lares no iónicos (gas, sustancia piedades físico-químicas, así ciones y procedimientos radio- hidrosoluble o liposoluble) en como los efectos secundarios lógicos. imagenología ha proliferado (quimiotoxicidad) de los medios en los últimos años debido a su de contraste intravasculares no Palabras clave: Medios de excepcional tolerancia por los iónicos. contraste intravasculares ioda- pacientes. La baja osmolalidad Conclusiones: Un factor que dos, medios de contraste ióni- de este tipo de medios de con- interviene en la incidencia de cos, medios de contraste no ió- traste aporta beneficios como reacciones idiosincráticas o aler- nicos. bajo incremento del volumen goides puede ser el estado psi- sanguíneo, baja toxicidad, bajo cológico del paciente. El trata- efecto sobre la barrera hema- miento previo con antihitamíni- toencefálica. cos, corticosteroides o ambos ha continúa en la pág. 130 1 Del Servicio de Radiología e Imagen “Dr. Carlos Coqui” del Hospital General de México osmolalidad o iso-osmolares. En los Estados Unidos 2 3 O.D. De la Universidad de Buenos Aires Cardiología.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]